表决结果：同意 7 票 反对 0 票 弃权 0 票 监事会发表意见如下： 1、公司 2023 年半年度报告编制和审议程序符合法律、法规、公司章程和公 司内部管理制度的各项规定； 2、公司 2023 年半年度报告的内容和格式符合中国证监会和证券交易所的各 项规定，所包含的信息能从各个方面真实地反映公司报告期的经营管理和财务状 况等事项； 股票代码：600327 股票简称：大东方 公告编号：临 2023－031 无锡商业大厦大东方股份有限公司 第八届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 无锡商业大厦大东方股份有限公司第八届监事会第十三次会议于 2023 年 8 月 22 日以通讯表决方式召开。本次监事会应参与审议监事 7 人，实际参加审议 表决监事 7 人。会议召开符合《公司法》和《公司章程》的规定。会议审议并通 过了以下议案： 一、《2023 年半年度报告》 二、《2023 年半年度经营数据简报》 表决结果：同意 7 票 反对 0 票 弃权 0 票 特此公告。 无锡商业大厦大东方股份有 ...

股票代码：600327 股票简称：大东方 公告编号：临 2023－023 无锡商业大厦大东方股份有限公司 2022 年度暨 2023 年第一季度业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 无锡商业大厦大东方股份有限公司（以下简称"公司"）分别于 2023 年 4 月 20 日、2023 年 4 月 28 日在上海证券交易所网站、《上海证券报》披露了公司 2022 年年度报告和 2023 年第一季度报告。为使广大投资者更深入了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 6 月 1 日（星 期四）上午 9:00-10:00 通过网络平台在线交流的方式举行"无锡商业大厦大东 方股份有限公司 2022 年度暨 2023 年第一季度业绩说明会"，就投资者关心的问 题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年一 季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披 ...

2023 年第一季度报告 证券代码：600327 证券简称：大东方 无锡商业大厦大东方股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年同期增减变动 | | | | --- | --- | --- | --- | --- | --- | | | | | 幅度(%) | | | | 营业收入 | 909,421,991.74 | | | | 5.96 | | 归属于上市公司股东的净利润 | 25,748,899.42 | | | | -55.03 | | 归属于上市公司股东的扣除非 经常性损益的净利润 | 13,401,626.32 | | | | -66.08 | | 经营活动产生的现金流量净额 | 202,040,894.22 | | | | 不适用 | | 基本每股收益（元/股） | | 0.029 | | | -55.03 | | 稀释每股收益（元/股） | | 0.029 | | | -55.03 | | 加权平 ...

Financial Performance - The company achieved a net profit of ¥190,206,150.52 for the year 2022, with a net profit attributable to shareholders of ¥174,263,895.76[5]. - The company's operating revenue for 2022 was ¥3,129,578,603.35, a decrease of 54.68% compared to ¥6,904,813,130.77 in 2021[24]. - The net profit attributable to shareholders for 2022 was ¥174,263,895.76, down 72.80% from ¥640,589,073.77 in 2021[24]. - The basic earnings per share for 2022 was ¥0.197, a decline of 72.79% compared to ¥0.724 in 2021[25]. - The company reported a net cash flow from operating activities of -¥140,234,049.02 in 2022, a decrease of 121.77% from ¥644,296,084.33 in 2021[24]. - The total assets at the end of 2022 were ¥5,492,937,354.40, down 33.45% from ¥8,253,970,595.74 at the end of 2021[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was only ¥9,889,321.32 in 2022, a significant drop of 93.43% from ¥150,577,510.64 in 2021[24]. Dividend Distribution - The proposed cash dividend is ¥0.70 per 10 shares, resulting in a total distribution of ¥61,934,566.26, which represents a cash dividend payout ratio of 35.54%[5]. - The board of directors has approved the profit distribution plan, which is subject to the approval of the annual general meeting[6]. - The total cash dividend amount distributed was 61,934,566.26 RMB, representing 35.54% of the net profit attributable to ordinary shareholders in the consolidated financial statements[174]. Acquisitions and Expansion - The company completed three acquisitions in the healthcare sector during 2022, including an 80% stake in "Jinhua Lianji Hospital" and a 68.1851% stake in "Zhibei Medical"[33]. - The pediatric healthcare business expanded to nearly 50 children's service chain institutions across more than 30 major cities in China[34]. - The company expanded its medical health services, acquiring "Zhibei Medical" and "Jinhua Lianji Hospital," and further increasing its stake in "Jiankao Pediatrics" to enhance its healthcare service capabilities[54]. - The company aims to focus on pediatric healthcare, targeting sub-specialties such as pediatric endocrinology and psychology, and aims to enhance the asset and revenue structure of the healthcare business[133]. Operational Efficiency and Cost Management - The company is restructuring its organization to enhance operational efficiency, aiming for a streamlined and flexible structure to improve management effectiveness[47]. - The company has implemented cost reduction and efficiency enhancement measures, focusing on investment evaluation and dynamic tracking of new projects, leading to improved profitability[49]. - The company is focused on enhancing its operational efficiency by optimizing approval processes and reducing hidden costs[49]. - The company has optimized its supermarket and convenience store models, achieving a new product launch rate of 10% with 856 new SKUs, while closing underperforming stores to enhance profitability[42]. Risk Management and Compliance - The company has outlined potential risks in its management discussion and analysis section, emphasizing the importance of investor awareness regarding these risks[8]. - The company has established a comprehensive internal control system, transitioning from compliance audits to management audits, enhancing risk control measures and compliance awareness[50]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[8]. - The company has not reported any violations of decision-making procedures regarding external guarantees[8]. Market Trends and Strategic Focus - The company plans to focus on pediatric and orthopedic healthcare, capitalizing on favorable policies and the growing demand for children's medical services[118]. - The healthcare sector is expected to see increased competition from public hospitals, necessitating improvements in management and service quality for private healthcare providers[118]. - The macroeconomic policies in 2023 emphasize expanding domestic demand and improving consumption conditions, setting a positive tone for the retail industry[106]. - The orthopedic market is experiencing strong demand, with a focus on chronic bone disease management and rehabilitation services for adolescents and the elderly[119]. Employee and Management Structure - The company has a total of 2,747 employees, with 454 in the parent company and 2,293 in major subsidiaries[167]. - The technical staff comprises 1,091 employees, representing a significant portion of the workforce[167]. - The company has implemented a salary policy that emphasizes performance and competitiveness, aligning compensation with economic indicators[168]. - The company has established a performance evaluation and incentive mechanism for senior management, linking performance pay to annual profit and operational performance[175]. Corporate Governance - The audit committee held 6 meetings during the reporting period, addressing key financial reports and internal control evaluations[163]. - The board of directors held a total of 8 meetings throughout the year, ensuring active governance[160]. - The company has no reported penalties from securities regulatory agencies in the past three years[159]. - There were no dissenting opinions raised by the board members regarding company matters during the reporting period[162].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,548,317,187.03, a decrease of 63.56% compared to ¥4,248,596,040.33 in the same period last year[18]. - Net profit attributable to shareholders was ¥159,157,866.23, representing a 4.99% increase from ¥151,591,658.73 in the previous year[18]. - The net cash flow from operating activities was -¥61,386,433.17, a decline of 117.02% compared to ¥360,625,787.46 in the same period last year[18]. - Total assets decreased by 30.07% to ¥5,772,150,611.49 from ¥8,253,970,595.74 at the end of the previous year[18]. - The net assets attributable to shareholders decreased by 4.20% to ¥3,448,007,242.52 from ¥3,599,088,859.93 at the end of the previous year[18]. - Basic earnings per share increased by 5.26% to ¥0.180 from ¥0.171 in the same period last year[19]. - The weighted average return on net assets was 4.12%, a slight decrease from 4.15% in the previous year[19]. - The company reported a 66.59% decrease in net profit after deducting non-recurring gains and losses, down to ¥39,865,429.71 from ¥119,335,293.09 in the previous year[18]. - The company achieved a revenue of 1.548 billion RMB and a net profit of 179.02 million RMB in the first half of 2022, with a net profit attributable to shareholders of 159.16 million RMB[25]. Revenue Breakdown - The department store business generated a revenue of 356 million RMB, a decrease of 6.11% compared to the same period in 2021, with a gross profit of 141.62 million RMB, down 16.53% year-on-year[25]. - The "San Feng Qiao" food segment reported a revenue of 69.53 million RMB, a decline of 20.97% year-on-year[27]. - The restaurant segment under "San Feng Qiao" achieved a revenue of 26.37 million RMB, down 16.54% year-on-year[27]. - The medical health segment generated a revenue of 1.058 billion RMB with a gross profit of 102 million RMB during the reporting period[27]. Investments and Acquisitions - The company completed the acquisition of a 68.19% stake in "Zhi Bei Medical" for a total investment of 27.75 million RMB[30]. - The company invested 600 million RMB in the Shanghai Jidaohang New Energy Development Partnership to explore opportunities in the new energy vehicle sector[28]. - The company transferred a 21% stake in "Junxu Real Estate" for 92.90 million RMB, optimizing its financial and debt structure[28]. - The company opened 6 new "San Feng Qiao" direct stores while closing 2 underperforming ones during the reporting period[27]. Cash Flow and Liquidity - Operating costs decreased by 65.80% to ¥1,240,249,375.51 from ¥3,626,659,331.08 year-on-year[31]. - The net cash flow from investment activities decreased by 402.70% to -¥402,842,575.94 from ¥133,083,693.00 year-on-year[31]. - The net cash flow from financing activities was -¥407,151,532.38, a decrease of 349.94% compared to ¥162,900,872.32 in the previous year[31]. - Total assets at the end of the reporting period were significantly impacted, with cash and cash equivalents decreasing by 52.27% to ¥794,838,000.85 from ¥1,665,443,275.09[37]. Shareholder Information - Total number of ordinary shareholders as of the end of the reporting period is 41,031[64]. - The largest shareholder, Jiangsu Wuxi Commercial Building Group Co., Ltd., holds 395,552,372 shares, accounting for 44.71% of total shares[66]. - The second largest shareholder, Industrial and Commercial Bank of China - Fortune CSI Dividend Index Enhanced Securities Investment Fund, holds 24,753,336 shares, representing 2.80%[66]. - The third largest shareholder, China Construction Bank - Da Cheng CSI Dividend Index Securities Investment Fund, holds 11,288,752 shares, which is 1.28% of total shares[66]. Risk and Legal Matters - The company did not declare any profit distribution or capital reserve transfer for the half-year period, with no dividends or stock bonuses proposed[48]. - The company has not faced any significant changes in risks during the reporting period, as detailed in the 2021 annual report[43]. - There were no major lawsuits or arbitration matters reported during the reporting period[55]. Future Plans and Strategic Focus - The company is focusing on expanding its medical health services and enhancing its operational management capabilities[27]. - The company plans to invest 60 million yuan in a partnership for renewable energy development, which is currently in progress[58]. - The company has plans for market expansion and new product development, although specific details were not disclosed in the financial report[76]. - The company has identified strategic opportunities for mergers and acquisitions to enhance its market position[81]. Accounting Policies and Financial Reporting - The company adheres to enterprise accounting standards, ensuring that financial statements reflect true and complete financial conditions[116]. - The company’s accounting policies include methods for recognizing revenue and estimating bad debt provisions[115]. - The company applies a straight-line method to allocate lease payments over the lease term for both operating and financing leases[195][197]. - The company recognizes provisions when there is a present obligation that is likely to result in an outflow of economic benefits[182].

Financial Performance - The company's operating revenue for Q1 2022 was ¥858,261,986.88, representing a decrease of 60.02% compared to the same period last year[3]. - The net profit attributable to shareholders was ¥57,257,514.55, down 46.95% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥39,513,943.38, a decline of 63.20% compared to the previous year[3]. - Basic and diluted earnings per share were both ¥0.065, down 46.95% year-on-year[3]. - The decline in revenue and profit was primarily due to the disposal of the automotive business and the impact of the newly added medical services[6]. - Total revenue for Q1 2022 was ¥858,261,986.88, a significant decrease of 60% compared to ¥2,146,729,588.54 in Q1 2021[17]. - Net profit for Q1 2022 was ¥69,320,742.86, compared to ¥110,220,453.23 in Q1 2021, indicating a decline of approximately 37%[17]. - The total comprehensive income for Q1 2022 was ¥69,108,867.60, down from ¥77,880,582.80 in Q1 2021, reflecting a decline of approximately 11%[18]. - The basic and diluted earnings per share for Q1 2022 were both ¥0.065, compared to ¥0.122 in Q1 2021, indicating a decrease of 46.7%[18]. Cash Flow - The net cash flow from operating activities was -¥26,218,840.44, reflecting a decrease of 114.37%[3]. - Cash flow from operating activities for Q1 2022 was negative at -¥26,218,840.44, a significant decline from ¥182,410,301.64 in Q1 2021[21]. - Cash inflow from operating activities totaled ¥1,459,197,692.06 in Q1 2022, down 53.7% from ¥3,145,141,803.50 in Q1 2021[21]. - Cash outflow from operating activities was ¥1,485,416,532.50 in Q1 2022, compared to ¥2,962,731,501.86 in Q1 2021, a decrease of 49.9%[21]. - The net cash flow from investing activities was -¥156,026,125.89 in Q1 2022, compared to ¥168,841,535.86 in Q1 2021, indicating a shift towards negative cash flow[22]. - The net cash flow from financing activities for Q1 2022 was -¥220,968,597.09, a decline from positive cash flow of ¥85,823,564.37 in Q1 2021[22]. - The ending cash and cash equivalents balance for Q1 2022 was ¥1,168,196,437.06, down from ¥1,319,555,464.61 in Q1 2021, reflecting a decrease of approximately 11.4%[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥8,357,139,375.11, an increase of 1.25% from the end of the previous year[3]. - The company's total assets as of March 31, 2022, amounted to ¥8,357,139,375.11, an increase from ¥8,253,970,595.74 at the end of 2021[14]. - Current assets totaled ¥4,102,794,655.46, slightly down from ¥4,111,312,056.17 at the end of 2021[12]. - Inventory increased to ¥2,474,342,746.76 from ¥2,229,129,537.26, representing an increase of approximately 11%[12]. - Current liabilities decreased to ¥3,792,788,423.15 from ¥3,854,841,262.31, a reduction of about 1.6%[13]. - Non-current liabilities rose to ¥572,347,934.35 from ¥481,129,193.34, marking an increase of approximately 19%[14]. - The company's equity attributable to shareholders increased to ¥3,656,513,485.51 from ¥3,599,088,859.93, reflecting a growth of about 1.6%[14]. - The equity attributable to shareholders was ¥3,656,513,485.51, up 1.60% from the end of the previous year[3]. - The company reported a significant increase in long-term receivables, rising to ¥37,863,497.90 from ¥33,470,759.77, an increase of approximately 13%[12]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,297[8]. - The net profit attributable to the parent company for Q1 2022 was ¥57,257,514.55, a decrease of 47% compared to ¥107,925,083.91 in Q1 2021[18].

Financial Performance - In 2021, the company achieved a net profit of RMB 670,145,586.46, with a net profit attributable to shareholders of the listed company amounting to RMB 640,589,073.77[5]. - The company's operating revenue for 2021 was approximately ¥6.90 billion, a decrease of 13% compared to ¥7.94 billion in 2020[22]. - Net profit attributable to shareholders increased by 103.32% to approximately ¥640.59 million in 2021 from ¥315.07 million in 2020[22]. - Basic earnings per share rose to ¥0.724 in 2021, reflecting a 103.37% increase from ¥0.356 in 2020[23]. - The weighted average return on equity increased to 23.30% in 2021, up by 14.14 percentage points from 9.16% in 2020[23]. - The gross profit margin for the overall business was 40.47% in 2021, slightly down from 42.04% in 2020[47]. - The gross profit margin for the "San Feng Qiao" dining segment was 45.89% in 2021, down from 54.29% in 2020[52]. - The medical health segment reported operating revenue of 107,623 million yuan in 2021, with a gross profit margin of 7.70%[54]. - The company achieved operating revenue of 6.905 billion RMB, a decrease of 13.00% year-on-year[60]. - Operating costs decreased by 14.87% to 5.881 billion RMB compared to the previous year[62]. Dividend Distribution - The proposed cash dividend distribution is RMB 3.50 per 10 shares, totaling RMB 309,672,831.30 based on a total share capital of 884,779,518 shares[5]. - The board of directors has approved the profit distribution plan, which is subject to the approval of the annual general meeting[6]. - The company approved a cash dividend distribution plan for the 2020 fiscal year, distributing a total of 221,194,879.50 CNY, which is 2.50 CNY per 10 shares[152]. - The company also approved a cash dividend distribution plan for the first half of 2021, with the same distribution amount of 221,194,879.50 CNY, again at 2.50 CNY per 10 shares[153]. Corporate Governance - The company has established a robust corporate governance structure to ensure compliance with legal requirements and protect shareholder interests[127]. - The company maintains independence from its controlling shareholder, ensuring that decision-making and operations are conducted separately[130]. - The company has conducted several shareholder meetings in 2021, with resolutions published on designated websites for transparency[131]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 8.1722 million yuan[138]. - The company has a total of 6 independent directors, with no changes in their shareholdings during the reporting period[138]. - The remuneration assessment process is overseen by the board's compensation and assessment committee, ensuring alignment with performance metrics[138]. - The company has complied with the requirements of the China Securities Regulatory Commission regarding corporate governance self-inspection[160]. Operational Developments - The company has opened 5 new supermarket stores and completed the renovation of 2 stores during the reporting period, showing positive year-on-year growth[31]. - The company signed contracts for 15 new direct stores in the Sanfengqiao food segment and established a franchise system for expansion[33]. - The company has successfully signed and opened 2 pilot franchise stores in the 7-Eleven convenience store business, optimizing product structure and reducing store construction costs[34]. - The company has streamlined its organizational structure to improve operational efficiency, aiming for a "lean, efficient, and flexible" organization[40]. - The company has established a digital transformation strategy, enhancing capabilities in marketing, service, operations, management, and decision-making, including the implementation of a BI platform for financial budgeting[42]. - The company has completed a major asset restructuring, divesting its traditional fuel vehicle sales and service business to focus on high-margin retail and healthcare sectors[38]. - The company has expanded its retail business, with "Dadongfang Department Store" targeting high-end consumers and maintaining a stable partnership with nearly 1,000 quality suppliers[46]. Market and Industry Trends - In 2021, the overall consumption market showed a gradual recovery, with retail sales growth stabilizing and consumer demand being released steadily[99]. - The number of newly opened shopping centers in 2021 was 545, the lowest in five years, while the total area of newly opened shopping centers increased by 35% compared to 2020, reaching 4,768 million square meters[104]. - The demand for medical services is expected to grow due to factors such as an aging population and increased health awareness among residents[108]. - The healthcare sector is shifting towards differentiated development, focusing on quality and efficiency rather than just scale expansion[101]. - The consumer sentiment in the food and beverage industry is under pressure due to the pandemic, but there is potential for growth in delivery and online services[100]. Strategic Initiatives - The company has initiated a dual-core strategy focusing on modern retail and healthcare, positioning itself as a leader in the Jiangsu region[45]. - The company plans to focus on pediatric and orthopedic sectors as core strategic investment areas in its medical health business for 2022[119]. - The company aims to enhance the operational quality of its department stores and transition towards a multi-format business model[114]. - The company intends to expand its "San Feng Qiao" food brand across the Jiangsu, Zhejiang, and Shanghai regions, enhancing market recognition[114]. - The company will continue to invest in and acquire medical health businesses to increase their asset and revenue scale within its structure[114]. Risk Management - The company has outlined potential risks in its management discussion and analysis section, emphasizing the importance of investor awareness regarding these risks[8]. - The company faces macroeconomic risks, including uncertainties from economic transitions and the ongoing challenges posed by the COVID-19 pandemic, which may impact consumer confidence and demand[122]. - The competitive landscape in the consumer sector includes challenges from e-commerce and new consumption models, putting pressure on traditional retail and healthcare services[123]. - The company is committed to addressing management and operational risks, particularly in the healthcare sector, by enhancing talent development and risk management capabilities[124]. Audit and Compliance - The company has received a standard unqualified audit report from the auditing firm Tianye[9]. - The internal control system has been continuously updated and improved, with no significant issues found during the internal control evaluation in the reporting period[156]. - All subsidiaries were effectively controlled during the reporting period, with no major deficiencies in management control[158]. - The company received a standard unqualified opinion in the internal control audit report for the 2021 fiscal year[160].

Financial Performance - The company's operating revenue for Q3 2021 was ¥1,821,163,254.38, a decrease of 16.71% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2021 reached ¥250,082,634.34, an increase of 815.58% year-on-year[2]. - The net profit excluding non-recurring gains and losses was ¥5,754,390.49, down 61.28% compared to the previous year[2]. - Total operating revenue for the first three quarters of 2021 reached ¥6,069,759,294.71, an increase of 10.1% compared to ¥5,510,049,674.11 in the same period of 2020[13]. - Operating profit for the first three quarters of 2021 was ¥648,793,858.13, significantly up from ¥195,733,762.45 in the previous year, marking a growth of 231.5%[13]. - Net profit for the first three quarters of 2021 was ¥422,692,825.42, compared to ¥155,335,330.22 in the same period of 2020, representing a year-over-year increase of 172.5%[14]. - The company reported a total comprehensive income of ¥371,149,436.75 for the first three quarters of 2021, compared to ¥201,958,667.44 in the same period of 2020, indicating a growth of 83.8%[14]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,935,577,379.19, an increase of 11.79% from the end of the previous year[2]. - The company's total assets amounted to RMB 7,935,577,379.19, an increase from RMB 7,098,957,774.99 at the end of 2020, representing a growth of approximately 11.7%[9]. - The total non-current assets reached RMB 3,785,698,667.92, up from RMB 3,387,699,360.37, indicating an increase of approximately 11.7%[10]. - Total liabilities increased to ¥4,270,731,430.53 in Q3 2021 from ¥3,495,876,135.98 in Q3 2020, an increase of 22.2%[11]. - The company’s total liabilities increased to RMB 3,080,589,799.61, reflecting a rise of approximately 5.7% compared to the previous year[10]. - Total liabilities reached approximately $3.5 billion, reflecting an increase of $152 million from the last reporting period[22]. - Current liabilities totaled approximately $2.9 billion, unchanged from the previous period[21]. - Non-current liabilities were approximately $580 million, showing an increase of $152 million compared to the previous period[22]. Equity and Investments - The weighted average return on equity increased by 6.58 percentage points to 7.32%[2]. - Long-term equity investments increased by 196.91% primarily due to the disposal of the automotive business[3]. - Long-term equity investments increased significantly to RMB 1,439,905,705.29 from RMB 484,961,617.90, marking a growth of approximately 196.5%[10]. - Shareholders' equity stood at approximately $3.6 billion, with no change from the previous reporting period[22]. - The company reported goodwill of approximately $23.17 million[21]. - Deferred income tax assets were approximately $18.67 million[21]. - The capital reserve was approximately $137 million[22]. - Undistributed profits amounted to approximately $1.37 billion[22]. Cash Flow and Operating Activities - Operating cash inflow for the first three quarters of 2021 reached ¥8,661,705,030.04, an increase of 20.7% compared to ¥7,171,135,205.52 in the same period of 2020[16]. - Net cash flow from operating activities was ¥432,118,207.48, a significant recovery from a negative cash flow of -¥70,173,843.21 in the first three quarters of 2020[16]. - Total cash inflow from investment activities was ¥337,455,749.67, down from ¥800,762,013.24 in the previous year, indicating a decrease of 57.9%[17]. - Cash outflow for investment activities totaled ¥215,754,971.84, compared to ¥428,958,778.88 in the same period last year, reflecting a reduction of 49.7%[17]. - Cash inflow from financing activities amounted to ¥2,373,893,328.32, an increase of 46% from ¥1,627,738,273.32 in the previous year[17]. - Net cash flow from financing activities was -¥149,444,955.73, slightly worse than -¥134,289,881.56 in the same period of 2020[17]. - The ending balance of cash and cash equivalents was ¥1,286,854,092.32, up from ¥601,368,497.25 at the end of the third quarter of 2020, representing a growth of 113.5%[17]. - Total cash paid for operating activities was ¥8,229,586,822.56, an increase of 13.6% compared to ¥7,241,309,048.73 in the previous year[16]. - Cash paid to employees increased to ¥379,432,700.40 from ¥310,065,438.57, marking a rise of 22.3% year-over-year[16]. Business Operations and Strategic Initiatives - The company reported a significant decrease in accounts receivable by 53.82% due to the disposal of its automotive business[3]. - The company plans to expand its market presence through new projects, including renovations of shopping malls and food factories[3]. - The company sold 51% equity stakes in Wuxi Commercial Building Group Dongfang Automobile Co., Ltd. and Wuxi New Era Automobile Trading Group Co., Ltd., resulting in the automotive business no longer being included in the consolidated scope from September[8]. - The company’s subsidiary, Shanghai Junyao Medical Health Technology Co., Ltd., acquired a 40.6667% stake in Jiankang Medical Technology (Shanghai) Co., Ltd. and a 51% stake in Shuyang County Central Hospital Co., Ltd., which were included in the consolidated scope from July[8]. - The company's inventory as of September 30, 2021, was RMB 1,986,039,419.02, slightly up from RMB 1,968,084,661.75 at the end of 2020, showing a marginal increase of about 0.9%[10]. - The company experienced a 100% increase in right-of-use assets due to the impact of new leasing standards[4].

Financial Performance - The company achieved a net profit of ¥153,070,497.82 for the first half of 2021, with the net profit attributable to shareholders of the listed company being ¥151,591,658.73[4]. - Basic earnings per share increased by 27.61% to ¥0.171 compared to the same period last year[20]. - The weighted average return on net assets rose to 4.15%, an increase of 0.73 percentage points from the previous year[20]. - The company reported a net profit available for distribution to shareholders of ¥582,831,891.77 based on the parent company financial statements[4]. - The net profit attributable to the parent company was ¥62,569,741.82 for the first half of 2021[4]. - Net profit attributable to shareholders reached RMB 151.59 million, up 27.56% compared to the same period last year[6]. - The company achieved operating revenue of RMB 4.25 billion in the first half of 2021, representing a year-on-year increase of 27.83%[6]. - The company’s total equity decreased to ¥2,669,804,941.25 as of June 30, 2021, down from ¥2,808,146,838.53 at the end of 2020, representing a decline of 4.9%[78]. - The company reported a net loss of 221,194,879.50 RMB during the current period, which is a significant increase from the loss of 159,260,313.24 RMB in the previous year[99]. Dividend Distribution - The proposed cash dividend distribution is ¥2.50 per 10 shares, totaling ¥221,194,879.50 based on the total share capital of 884,779,518 shares as of June 30, 2021[4]. - The company plans to submit the profit distribution proposal to the second extraordinary general meeting of shareholders in 2021 for approval[5]. - The company plans to distribute a cash dividend of 2.50 CNY per 10 shares for the first half of 2021[49]. - The company distributed dividends totaling ¥241,610,034.54 in the first half of 2021, compared to ¥179,462,862.25 in the same period of 2020, reflecting a growth of approximately 34.6%[89]. Revenue and Operating Activities - The net cash flow from operating activities was RMB 360.63 million, a significant increase of 228.22% year-on-year[6]. - The retail business segment generated revenue of RMB 3.79 billion, a growth of 38.23% year-on-year, with a gross profit of RMB 169.67 million, up 44.38%[27]. - The automotive sales and service segment reported revenue of RMB 3.60 billion, a year-on-year increase of 27.15%, with a gross profit of RMB 272 million, up 15.14%[29]. - The company achieved operating revenue of 4.25 billion RMB, a year-on-year increase of 27.83%[34]. - The total operating revenue for the first half of 2021 reached ¥4,248,596,040.33, an increase of 27.8% compared to ¥3,323,535,586.67 in the same period of 2020[81]. Assets and Liabilities - The company’s total assets increased by 14.02% year-on-year, reaching RMB 8.09 billion at the end of the reporting period[6]. - The company reported a decrease in long-term equity investments by 15.71 million RMB, mainly due to the impact of equity accounting for associated companies[40]. - Total liabilities reached ¥4,534,280,227.80, up from ¥3,495,876,135.98, marking an increase of 29.7%[74]. - Current assets totaled ¥4,682,125,446.20, an increase of 26.1% from ¥3,711,258,414.62 at the end of 2020[72]. - Short-term borrowings rose by 50.15% to 1.35 billion RMB, primarily to supplement working capital[39]. Strategic Initiatives - The company initiated a strategic plan to gradually cultivate the medical health business as a new core area, establishing a platform for business expansion in this sector[30]. - The company plans to enhance its online sales channels and explore new marketing strategies, including live streaming sales[26]. - The company is in the process of selling 51% equity stakes in its subsidiaries "Dongfang Automobile" and "New Era Automobile" to its controlling shareholder[58]. Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 34,333[64]. - The largest shareholder, Jiangsu Wuxi Commercial Building Group Co., Ltd., held 395,552,372 shares, representing 44.71% of total shares[66]. - The second largest shareholder, China Merchants Bank Co., Ltd. - SSE Dividend ETF, increased its holdings by 1,718,542 shares to 38,408,794 shares, accounting for 4.34%[66]. Risk and Compliance - The report includes a risk statement regarding future plans and development strategies, highlighting uncertainties[6]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[7]. - There were no violations of decision-making procedures regarding external guarantees[7]. Financial Management and Accounting - The company adheres to the enterprise accounting standards, ensuring that its financial reports accurately reflect its financial status and operational results[113]. - The company prepares consolidated financial statements based on its own and subsidiaries' financial reports, reflecting the overall financial status, operating results, and cash flows of the entire corporate group[120]. - The company recognizes investment income based on the fair value of equity held before the acquisition date when control over the investee is obtained[122]. Inventory and Asset Management - The company's inventory includes finished goods, raw materials, and real estate development products, with classifications for completed, under-construction, and planned development products[146]. - Inventory valuation is based on cost, including procurement and processing costs, with a weighted average method used for inventory issuance[146]. - The net realizable value of inventory is determined based on estimated selling prices minus estimated costs and taxes, with impairment provisions calculated at the end of the period[147]. Employee Benefits and Compensation - Short-term employee compensation is recognized as a liability and included in current period expenses[178]. - Defined benefit plans are measured using the projected unit credit method, with obligations discounted using market yields on high-quality corporate bonds[179]. - Termination benefits are recognized when the company cannot withdraw the offer of benefits, with related costs included in current period expenses[182].